Ron Wald




Ron Wald is a nephrologist and Associate Professor of Medicine at the University of Toronto. A native of Montreal, he completed his undergraduate and medical degrees at McGill University and continued his clinical training in internal medicine and nephrology at the University of Toronto. Following this, he completed a Master in Public Health at Harvard University and a research fellowship at Tufts Medical Center in Boston. Since joining the St. Michael’s Hospital Division of Nephrology in 2006, Dr. Wald has been responsible for the hospital’s acute dialysis program. In addition to attending on the hospital’s Nephrology consult and ward services, he provides longitudinal care for patients on chronic hemodialysis and has an active general nephrology practice.

Dr. Wald’s research interests are in the areas of critical care nephrology and chronic dialysis. He is currently leading a Canadian Institutes of Health Research-funded international trial on the impact of the timing of dialysis initiation on survival in critically ill patients with acute kidney injury. He also has a strong interest in the long-term outcomes of patients who survive an episode of acute kidney injury and is co-leading a trial that is comparing specialized nephrology care vs usual care in this population. In the chronic dialysis area, Dr. Wald co-led a CIHR-funded study on the cardiovascular benefits of incentre nocturnal hemodialysis. He recently completed a multicentre pilot trial examining the implementation of two different levels of serum phosphate control in the hemodialysis population. A larger definitive trial to evaluate whether intensive serum phosphate lowering mediates improved clinical outcomes is planned. As a founding member of the Kidney Dialysis and Transplantation Program of the Institute for Clinical Evaluative Sciences, Dr. Wald is also involved in several studies that are using province-wide administrative data to answer research questions in kidney disease.

Please note: Dr. Wald is not taking any summer students.

Recent Publications

  1. Noori, N, Sharma Parpia, A, Wald, R, Goldstein, MB. Validation of the SMH Equations for the Estimation of the Total Body Water Volume in Hemodialysis Patients. Can J Kidney Health Dis. 2022;9 :20543581221137180. doi: 10.1177/20543581221137180. PubMed PMID:36438438 PubMed Central PMC9685218.
  2. Wald, R, Kirkham, B, daCosta, BR, Ghamarian, E, Adhikari, NKJ, Beaubien-Souligny, W et al.. Fluid balance and renal replacement therapy initiation strategy: a secondary analysis of the STARRT-AKI trial. Crit Care. 2022;26 (1):360. doi: 10.1186/s13054-022-04229-0. PubMed PMID:36424662 PubMed Central PMC9694606.
  3. MyTEMP writing committee. Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial. Lancet. 2022;400 (10364):1693-1703. doi: 10.1016/S0140-6736(22)01805-0. PubMed PMID:36343653 .
  4. Bagshaw, SM, Neto, AS, Smith, O, Weir, M, Qiu, H, Du, B et al.. Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARRT-AKI trial. Intensive Care Med. 2022;48 (12):1736-1750. doi: 10.1007/s00134-022-06912-w. PubMed PMID:36331570 .
  5. Khondker, A, Groff, M, Nunes, S, Sun, C, Jawa, N, Lee, J et al.. KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors: Description of Clinical Research Protocol of the KINDEST-CCS Study. Can J Kidney Health Dis. 2022;9 :20543581221130156. doi: 10.1177/20543581221130156. PubMed PMID:36325265 PubMed Central PMC9618744.
  6. Mathew, RO, Maron, DJ, Anthopolos, R, Fleg, JL, O'Brien, SM, Rockhold, FW et al.. Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial. Circ Cardiovasc Qual Outcomes. 2022;15 (10):e008995. doi: 10.1161/CIRCOUTCOMES.122.008995. PubMed PMID:36193750 PubMed Central PMC9588677.
  7. Abdulmonem L Hashem, D, Chan, VSH, Hanneman, K, Wald, RM, Thavendiranathan, P, Ouzounian, M et al.. Association of Pectus Excavatum With Ventricular Remodelling and Mitral Valve Abnormalities in Marfan Syndrome. Can Assoc Radiol J. 2022; :8465371221127236. doi: 10.1177/08465371221127236. PubMed PMID:36164999 .
  8. Jayne, D, Walsh, M, Merkel, PA, Peh, CA, Szpirt, W, Puéchal, X et al.. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. Health Technol Assess. 2022;26 (38):1-60. doi: 10.3310/PNXB5040. PubMed PMID:36155131 .
  9. Ostermann, M, Bagshaw, SM, Lumlertgul, N, Wald, R. Indications for and Timing of Initiation of KRT. Clin J Am Soc Nephrol. 2022; :. doi: 10.2215/CJN.05450522. PubMed PMID:36100262 .
  10. Wald, R, Beaubien-Souligny, W, Chanchlani, R, Clark, EG, Neyra, JA, Ostermann, M et al.. Delivering optimal renal replacement therapy to critically ill patients with acute kidney injury. Intensive Care Med. 2022;48 (10):1368-1381. doi: 10.1007/s00134-022-06851-6. PubMed PMID:36066597 .
Search PubMed

Affiliations & Other Activities

  • Nephrologist, Department of Medicine, St. Michael’s Hospital
  • Associate Professor, Department of Medicine, University of Toronto